Skip to main content
NASDAQ:ADPT

Adaptive Biotechnologies Competitors

$32.91
-0.23 (-0.69 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.03
$33.59
50-Day Range
$32.22
$44.59
52-Week Range
$30.41
$71.25
Volume1.68 million shs
Average Volume998,060 shs
Market Capitalization$4.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.35

Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) Vs. TECH, ARGX, QGEN, NVAX, RGEN, and NBIX

Should you be buying ADPT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Adaptive Biotechnologies, including Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

Adaptive Biotechnologies (NASDAQ:ADPT) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
Bio-Techne32.69%12.20%8.09%

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and Bio-Techne, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Bio-Techne03702.70

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Bio-Techne has a consensus target price of $396.1111, suggesting a potential downside of 3.12%. Given Adaptive Biotechnologies' higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Bio-Techne.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Bio-Techne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
Bio-Techne$738.69 million21.53$229.30 million$3.86105.93

Bio-Techne has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bio-Techne beats Adaptive Biotechnologies on 11 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and argenx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
argenxN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and argenx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
argenx071102.61

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. argenx has a consensus target price of $297.8750, suggesting a potential upside of 15.36%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than argenx.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, argenx has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and argenx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
argenx$78.17 million169.47$-182,520,000.00($4.73)-54.59

Adaptive Biotechnologies has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 54.2% of argenx shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Adaptive Biotechnologies beats argenx on 8 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
QIAGEN11.18%17.51%8.44%

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and QIAGEN, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
QIAGEN05902.64

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. QIAGEN has a consensus target price of $60.76, suggesting a potential upside of 31.29%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than QIAGEN.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Earnings & Valuation

This table compares Adaptive Biotechnologies and QIAGEN's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
QIAGEN$1.53 billion6.91$-41,460,000.00$1.4332.36

QIAGEN has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

QIAGEN beats Adaptive Biotechnologies on 9 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
Novavax-133.10%-1,346.17%-45.85%

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 49.9% of Novavax shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.3% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Adaptive Biotechnologies and Novavax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Novavax11502.57

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Novavax has a consensus target price of $190.9286, suggesting a potential upside of 49.37%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Novavax.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Novavax's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
Novavax$18.66 million507.52$-132,690,000.00($5.80)-22.04

Adaptive Biotechnologies has higher revenue and earnings than Novavax. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptive Biotechnologies beats Novavax on 10 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
Repligen13.40%6.58%5.00%

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adaptive Biotechnologies and Repligen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Repligen00503.00

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.81%. Given Adaptive Biotechnologies' higher probable upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Repligen.

Earnings and Valuation

This table compares Adaptive Biotechnologies and Repligen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
Repligen$270.24 million34.86$21.41 million$1.07160.37

Repligen has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats Adaptive Biotechnologies on 11 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Adaptive Biotechnologies and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
Neurocrine Biosciences8.96%18.18%9.50%

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adaptive Biotechnologies and Neurocrine Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Neurocrine Biosciences071302.65

Adaptive Biotechnologies presently has a consensus target price of $60.40, suggesting a potential upside of 83.53%. Neurocrine Biosciences has a consensus target price of $127.8333, suggesting a potential upside of 38.72%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Neurocrine Biosciences.

Earnings and Valuation

This table compares Adaptive Biotechnologies and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million54.28$-68,610,000.00($1.01)-32.58
Neurocrine Biosciences$788.10 million11.05$37.01 million$0.39236.28

Neurocrine Biosciences has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Neurocrine Biosciences beats Adaptive Biotechnologies on 10 of the 14 factors compared between the two stocks.

Ad Investing Trends
The #1 Way to Play the CBD Sector
A proprietary product line, unmatched distribution formula, and exponential growth potential in an explosive industry makes this company the top way to play the legal cannabis sector

Adaptive Biotechnologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
argenx logo
ARGX
argenx
1.3$258.21-0.4%$13.25 billion$78.17 million-54.59Upcoming Earnings
Analyst Upgrade
Gap Down
QIAGEN logo
QGEN
QIAGEN
1.7$46.28-0.2%$10.55 billion$1.53 billion57.14
Novavax logo
NVAX
Novavax
1.8$127.82-8.1%$9.47 billion$18.66 million-24.49Earnings Announcement
Analyst Report
Gap Down
Repligen logo
RGEN
Repligen
1.9$171.60-2.2%$9.42 billion$270.24 million209.27Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.15-0.8%$8.71 billion$788.10 million99.09Analyst Report
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$100.84-2.7%$7.64 billion$289.59 million-30.93Gap Down
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$121.17-0.7%$7.35 billion$73.99 million-46.78Earnings Announcement
News Coverage
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$72.29-7.9%$6.80 billion$10.68 million-39.29Earnings Announcement
Analyst Revision
Gap Down
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$51.17-6.5%$6.20 billion$26.68 million-23.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.48-0.5%$6.09 billion$195.99 million265.50Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$39.11-1.6%$5.09 billion$8.09 million-16.57Earnings Announcement
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99-1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Twist Bioscience logo
TWST
Twist Bioscience
1.6$91.08-9.4%$4.45 billion$90.10 million-24.29Earnings Announcement
Gap Down
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$66.88-1.0%$4.18 billion$20,000.00-4.76Earnings Announcement
Analyst Report
News Coverage
Gap Down
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$79.42-2.9%$4.07 billionN/A-34.23Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$26.08-1.6%$3.99 billionN/A-13.58Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$27.95-0.4%$3.96 billionN/A-13.12Analyst Revision
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.93-2.7%$3.43 billionN/A-40.19Earnings Announcement
Analyst Downgrade
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$27.61-2.9%$2.50 billionN/A0.00
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$51.83-7.6%$2.34 billion$125.57 million-30.31Earnings Announcement
Analyst Report
News Coverage
Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.65-0.0%$2.32 billion$50.04 million0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$12.49-2.8%$2.22 billion$48.83 million-16.43Earnings Announcement
Vericel logo
VCEL
Vericel
1.1$47.20-6.0%$2.19 billion$117.85 million-4,720,000.00Analyst Report
Analyst Revision
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$48.04-6.3%$2.16 billionN/A0.00Earnings Announcement
High Trading Volume
Editas Medicine logo
EDIT
Editas Medicine
1.6$31.72-3.4%$2.15 billion$20.53 million-18.23Earnings Announcement
Analyst Report
Gap Down
bluebird bio logo
BLUE
bluebird bio
1.8$29.85-1.2%$2.01 billion$44.67 million-2.72Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.8$23.25-8.5%$1.89 billionN/A-10.86Earnings Announcement
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.58-6.1%$1.89 billion$31.43 million-4.51
Ocugen logo
OCGN
Ocugen
1.0$8.61-15.0%$1.71 billionN/A-5.82Earnings Announcement
Analyst Report
Replimune Group logo
REPL
Replimune Group
1.5$36.05-2.9%$1.68 billionN/A-20.37
Immunovant logo
IMVT
Immunovant
1.6$15.63-1.0%$1.53 billionN/A-12.12Analyst Report
Unusual Options Activity
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$35.04-1.1%$1.51 billionN/A0.00Analyst Upgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.47-1.7%$1.51 billion$102.43 million-17.45Analyst Report
Analyst Revision
Curis logo
CRIS
Curis
0.9$16.27-39.6%$1.49 billion$10 million-19.84High Trading Volume
Unusual Options Activity
News Coverage
Trading Halted
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.81-2.8%$1.48 billion$35.23 million-14.04Earnings Announcement
Analyst Upgrade
AlloVir logo
ALVR
AlloVir
1.5$22.63-0.9%$1.47 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$62.71-4.7%$1.39 billionN/A-42.37Earnings Announcement
News Coverage
Alector logo
ALEC
Alector
1.3$16.79-0.4%$1.34 billion$21.22 million-7.53
Translate Bio logo
TBIO
Translate Bio
1.6$16.73-6.7%$1.26 billion$7.80 million-15.64Analyst Report
Analyst Revision
Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.13-0.1%$1.24 billion$100.56 million0.00Upcoming Earnings
News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.83-0.6%$1.16 billionN/A-2.99Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.3$36.57-0.6%$1.08 billionN/A-15.24Earnings Announcement
Insider Selling
News Coverage
Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.85-1.7%$1.05 billion$356.07 million6.79Earnings Announcement
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.85-5.9%$1.01 billionN/A-4.60Earnings Announcement
Analyst Revision
News Coverage
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.60-4.3%$983.64 million$20.49 million-11.87Upcoming Earnings
News Coverage
Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.67-7.1%$958.80 millionN/A0.00Earnings Announcement
News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.32-0.1%$937.02 million$42.74 million-225.78Earnings Announcement
Analyst Revision
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.69-2.3%$900.88 millionN/A0.00Analyst Revision
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$6.69-1.0%$867.31 million$32.16 million-7.60
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.